Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-12
2006-09-12
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S224000, C544S336000, C546S184000, C546S192000, C546S193000, C546S194000
Reexamination Certificate
active
07105505
ABSTRACT:
Disclosed are novel compounds of the formulawherein R1is optionally substituted benzimidazolyl or a derivative thereof; R2is optionally substituted aryl or heteroaryl; M1and M2are C(R3) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1receptor antagonist.
REFERENCES:
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 6211199 (2001-04-01), Kane et al.
patent: 2 387 613 (2001-05-01), None
patent: 0 580 541 (1994-01-01), None
patent: 0 626 373 (1994-11-01), None
patent: WO 98/06394 (1998-02-01), None
patent: 02/24659 (2002-03-01), None
patent: WO 02/32893 (2002-04-01), None
patent: WO 02/072570 (2002-09-01), None
“Abbot's H3 histamine receptor antagonist, ABT-239, a candidate treatment of cognitive disorders, ADHD, Alzheimer's and schizophrenia,” TherapeuticAdvances, LeadDiscovery's bulletin, www.leaddiscovery.co.uk, Jan. 2005, pp. 1-5.
Basic and Clinical Pharmacology, 7th edition, Bertram G. Katzung, pp. 268-269.
Janssens et al,Journal of Medicinal Chemistry, 28(12) (1985)1943-1947.
McLeod et al,Am. J. Rhinology, 13, 5 (1999), p. 391-399..
Taylor-Clark et al,Brit. J. Pharmacology, 144(2005), p. 867-874.
Leurs et al,TIPS, 19(1998), p. 177-183.
Henning et al,Journal of Medicinal Chemistry, vol. 30, 1987, pp. 814-819.
Hey et al,European Journal of Pharmacology, vol. 294 (1995) pp. 329-335.
Heinlsch et al,Monatshefte für Chemie, vol. 104 (1973), pp. 1372-1382.
U.S. Appl. No. 10/414,943.
U.S. Application, filed Jun. 20, 2003, “Indole Derivatives Useful as Histamine H3Anatagonists”(Claims Benefit of U.S. Appl. 60/390,987).
Aslanian Robert G.
Berlin Michael Y.
Boyce Christopher W.
Cao Jianhua
Kozlowski Joseph A.
Johnsen Jason H.
Russell Mark W.
Schering Corporation
Wilson James O.
LandOfFree
Benzimidazole derivatives useful as histamine H3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazole derivatives useful as histamine H3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole derivatives useful as histamine H3 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528207